WASHINGTON – Hoping to avoid future "flash crashes" like the one that played havoc with the markets May 6, 2010, the SEC is proposing changes to the circuit breaker rules it adopted nearly 25 years ago. Read More
Finding a partner in China is the single most important first step for Western biotechs that want to do business there and get a piece of the exploding pharmaceutical market, according to several authorities on starting up and doing business in China. Read More
Marshall Edwards Inc., of San Diego, raised $2 million through a private placement. The company sold 1.33 million shares to majority shareholder Novogen Ltd. Read More
Santen Pharmaceutical Co. Ltd., of Osaka, Japan, agreed to acquire shares representing 50.55 percent of the share capital of ophthalmology firm Novagali Pharma SA, of Paris, for a cash consideration of €6.15 (US$8.35), or about $136 million, marking a premium of 71.3 percent over the Sept. 27 trading price, which could be increased to €6.25. Read More
SanBio Inc., of Mountain View, Calif., reported that the first subject in a Phase I/IIa trial has been treated with SB623. The two-site study will evaluate 18 patients who have suffered an ischemic stroke within the past six to 24 months and have a motor neurological deficit. Read More
Onyx Pharmaceuticals Inc.'s submission of a new drug application (NDA) for its multiple myeloma drug, carfilzomib, is an audacious move that has investors biting their nails. The strength of the submission rests on study 003-A1, an open-label, single-arm Phase IIb trial in 266 heavily pretreated patients with relapsed and refractory multiple myeloma. Read More
After a long and winding road that included two Phase III detours, Chelsea Therapeutics International Ltd. moved forward with a new drug application (NDA) for its lead candidate Northera (droxidopa), an orally active synthetic precursor of norepinephrine, to treat symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and nondiabetic autonomic neuropathy. Read More
